コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 RNA level, and gynecologic examination with Papanicolaou smear.
2 women with an "adequate" history of negative Papanicolaou smears.
4 s on cytopathological examination of vaginal Papanicolaou smears after hysterectomy for benign gyneco
5 creening, annual Papanicolaou smears, annual Papanicolaou smears after two negative smears obtained 6
6 women, cervical cancer screening with annual Papanicolaou smears after two negative smears obtained 6
7 ated the success of this approach by imaging Papanicolaou smears and breast cancer tissue slides over
9 women appearing in the clinic for a routine Papanicolaou smear, and/or women seeking a routine gynec
10 emarkable, including for HIV, prior abnormal Papanicolaou smears, and other risk factors for human pa
11 Disease Control and Prevention), semiannual Papanicolaou smears, annual colposcopy, and semiannual c
12 n screening strategies--no screening, annual Papanicolaou smears, annual Papanicolaou smears after tw
13 ient receipt of gynecologic examinations and Papanicolaou smears, cholesterol screening, and fecal oc
15 sed controlled trials investigating cervical Papanicolaou smear collection devices were identified.
16 -reported receipt and timing of mammography, Papanicolaou smear, colonoscopy, or skin examination was
17 were then screened using 4 different tests: Papanicolaou smear, direct visual inspection of the cerv
18 in women aged 21 to 65 years with cytology (Papanicolaou smear) every 3 years or, for women aged 30
19 bs is less specific than but as sensitive as Papanicolaou smears for detecting high-grade cervical di
20 en with RA were more likely to receive >/= 1 Papanicolaou smear (hazard ratio [HR] 1.21, 95% confiden
22 about the frequency with which they received Papanicolaou smears, mammograms, and clinical breast exa
27 ding, discharge, abnormal glandular cells on Papanicolaou smear, or an endometrial measurement on ult
29 -up who had HR-HPV screening and cytology by Papanicolaou smear performed yearly between 2002 and 201
30 ndicated that most of the errors occurred in Papanicolaou smear reporting, which is consistent with t
31 relative risk, 1.15 [95% CI, 1.01 to 1.33]), Papanicolaou smear screening (relative risk, 2.29 [CI, 1
33 enrollees of 2 US health plans, we compared Papanicolaou smear screening histories of women aged 55-
35 Using literature review, we assessed (1) Papanicolaou smear screening recommendations after hyste
36 4% and 36% more likely to meet mammogram and Papanicolaou smear screening recommendations, respective
38 nefit compared with that given by semiannual Papanicolaou smear screening, and semiannual colposcopy
39 cifiCare enrollees who received mammography, Papanicolaou smear screening, chlamydia screening, diabe
40 ng (ie, screening for cervical cancer with a Papanicolaou smear, screening for gonorrhea and chlamydi
41 e a careful history, pelvic examination, and Papanicolaou smear, should be repeated annually while th
44 DNA in urine was associated with an abnormal Papanicolaou smear to the same extent that detection of
46 esting of self-collected vaginal samples and Papanicolaou smears were 17.1% (95% CI, 15.1%-19.3%) and
47 tudy subjects with a broom device, and after Papanicolaou smears were made, residual specimens were p
48 s of purified protein derivative testing and Papanicolaou smears were statistically significantly hig
49 women aged 65 years or older who have had a Papanicolaou smear within 3 years have decreased since 2
50 vors, 2743 of 3392 (80.9%) reported having a Papanicolaou smear within the recommended period, and 14